First Program

all catalysts(0)

nothing on the calendar yet

News(4)

• Boulevard starts up with $65M to pursue targeted autoimmune drugs
  Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.
  biopharma_dive · 1mo ago
• Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
  The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
  biopharma_dive · 1mo ago
• Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
  Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
  fiercebiotech · 2mo ago
• ‘We’re moving quickly’: Startup bags rare disease drug as Thiel-backed CEO eyes $50M fundraise
  A rare disease startup with a mission to repurpose proven drugs has licensed a Chinese formulation of a well-known medicine and set its sights on a $50 million fundraise.
  fiercebiotech · 2mo ago